MAPT and Alzheimer disease: Injection of the AAV-shCyp46a1 in the APP23 model of AD exacerbated their AD phenotype by increasing the Aβ content, tau phosphorylation, and neuronal loss leading to epileptic seizures (Chali et al., 2015; Djelti et al., 2015).